Wealth Enhancement Advisory Services »

Allogene Therapeutics shares owned by Wealth Enhancement Advisory Services

Quarter-by-quarter ownership of Allogene Therapeutics (ALLO) shares owned by Wealth Enhancement Advisory Services from 13F filings

Historical chart of Wealth Enhancement Advisory Services investment in Allogene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Allogene Therapeutics held by Wealth Enhancement Advisory Services consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allogene Therapeutics by Wealth Enhancement Advisory Services

Quarter filed Position value Share count Share price at filing
2025-09-30 $70k 52k 1.35
2025-06-30 $22k 19k 1.19
2025-03-31 $28k 19k 1.46

More positions owned by Wealth Enhancement Advisory Services

Ishares Tr Core S&p500 Etf (IVV)
Ishares Tr Core Us Aggbd Et (AGG)
Microsoft Corporation (MSFT)
Alps Etf Tr Smith Core Plus (SMTH)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Ishares Tr Msci Intl Moment (IMTM)
Amazon (AMZN)
J P Morgan Exchange Traded F Us Momentum (JMOM)
Schwab Strategic Tr Fundamental Intl (FNDF)
Victory Portfolios Ii Usaa Msci Usa Sm (USVM)
American Centy Etf Tr Us Large Cap Vlu (AVLV)
Ishares Tr Msci Usa Min Vol (USMV)
Ishares Tr Us Treas Bd Etf (GOVT)
Invesco Exchange Traded Fd T S&p500 Quality (SPHQ)
Vanguard Index Fds S&p 500 Etf Shs (VOO)

View all positions for Wealth Enhancement Advisory Services

Top funds holding Allogene Therapeutics

Pfizer
Tpg Gp A
BlackRock
Citadel Advisors
Vanguard Group
PRIMECAP Management Company
Woodline Partners
Frazier Life Sciences Management
Geode Capital Management
UBS Group
Millennium Management
Two Sigma Investments
Patient Square Capital
Wildcat Capital Management
Renaissance Technologies

View all funds holding Allogene Therapeutics